Guardant Health, Inc. revenue by segment GH

Annual Quarterly

Guardant Health, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Oncology at $683.6 million, 70% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019
Revenue	1,279	982	739	564	450	374	287	214
Oncology	845 +32.2% share 66.1%	684 +25.9% share 69.6%	543 +34.4% share 73.5%	404 share 71.6%	—	—	—	—
Biopharma Data	227 +10.3% share 17.7%	210 +18.3% share 21.4%	178 +30.2% share 24.0%	136 share 24.2%	—	—	—	—
Screening	197 +304.7% share 15.4%	80 +1456.0% share 8.1%	5 share 0.7%	—	—	—	—	—
Licensing Other	10 +6.3% share 0.7%	9 -36.5% share 0.9%	13 -43.1% share 1.8%	24 share 4.2%	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Services-Medical Laboratories (SIC 8071)
Listed as: GH (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Palo Alto, CA
SEC filer status: Large accelerated filer
SEC CIK: 1576280

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.